TrialDrug safety2022

RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability.

Ernest Nadal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.